Emerging Medical Device Market Expected to Exceed $400 Billion by 2023 - Seite 2

The Hygee self-sampling kit includes a discreet, wearable medical device that enables a woman to anonymously test for STIs such as chlamydia. Testing for this disease is particularly important for pregnant women, who must be screened for chlamydia infections to minimize the risk of transmission of the infection to their babies during childbirth. In any given year, approximately 8 million women give birth in the United States, Canada, Brazil, Mexico, Morocco, Djibouti, and Vietnam where Hygee will first be offered.

While this niche represents a considerable market for the Hygee medical device, opportunity exists well beyond pregnant women. The World Health Organization recommends that all sexually active women aged 15 to 25 get tested yearly for chlamydia, representing a market of about 500 million women worldwide.

Dr. Michel Aube, ETST's CEO and chief science officer, states, "No other existing method of collecting genital specimens from women is more convenient or more efficient than Hygee. Through intentional design, Hygee is a 'mistake proof' medical device with extremely simple instructions that allow any woman, regardless of age or education the assurance of correctly using the kit on the first try.  With roughly 130 million new chlamydia cases diagnosed yearly, according to the WHO, Hygee is dedicated to this area of women's health."

ETST's projections for Hygee anticipate strong sales growth in years two and three after product launch. As soon as year one, sales of Hygee and the associated in vitro molecular diagnoses should reach between $1.5 million and $2.5 million USD. Second year sales should reach $1 million monthly and up to $20 million yearly as early as the third year.  Read this and more news for ETST at https://www.financialnewsmedia.com/news-etst

Other recent developments and happenings in the biotech industry include:

TransEnterix, Inc. (NYSE: TRXC) was up slighly in early trading on Tuesday at $2.79 trading just over 340,000 shares by 10:00am Est. TransEnterix, a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, recently announced its naming to Deloitte's 2018 Technology Fast 500TM, an annual ranking of the fastest growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. "We're thrilled to be recognized as one of Deloitte's 2018 Technology Fast 500 companies," said Todd M. Pope, TransEnterix president and CEO. "TransEnterix's mission is to advance minimally invasive surgical capabilities through digital laparoscopy with the SenhanceTM Surgical System.